Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

14.950
-0.790-5.02%
Volume:1.23M
Turnover:18.76M
Market Cap:15.35B
PE:-17.18
High:15.700
Open:15.700
Low:14.950
Close:15.740
52wk High:30.800
52wk Low:14.800
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:0.95
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.870
ROE:-9.02%
ROA:-1.55%
PB:2.24
PE(LYR):-17.18
PS:4.08

Loading ...

European Capital Groups Flock to China for Deals as Chinese Innovative Drugs Enter Overseas Commercialization 4.0 Era (Concept Stocks Attached)

Stock News
·
Nov 09

JUNSHI BIO Registers Zero Share Movement in October 2026 and Reaffirms Public Float Compliance

Bulletin Express
·
Nov 04

Shanghai Junshi Biosciences Could Be 75% Below Fair Value As Losses Narrow

Simply Wall St.
·
Oct 31

Shanghai Junshi Biosciences (SEHK:1877) Stock Faces Q3 Earnings Loss Despite Revenue Growth

Simply Wall St.
·
Oct 30

JUNSHI BIO Narrows Net Loss Attributable to Shareholders by 75% to RMB 149 Million in First Three Quarters

Stock News
·
Oct 29

Junshi Biosciences Announces First Patient Dosed in Phase III Trial of JS207 Combined with JS007 for First-Line Treatment of Advanced Hepatocellular Carcinoma

Stock News
·
Oct 29

Hong Kong Stock Announcement Highlights: Ping An's First Three Quarters Net Profit Attributable to Shareholders Reaches 96.645 Billion Yuan, Continues to Deepen "Comprehensive Finance + Healthcare and Elderly Care" Dual-Wheel Parallel, Technology-Driven Strategy

Stock News
·
Oct 29

Junshi Biosciences Gains NMPA Acceptance for Subcutaneous Toripalimab NDA Targeting HER2-Positive Urothelial Carcinoma

Bulletin Express
·
Oct 28

Shanghai Junshi Biosciences - Receives Supplemental Drug Approval from Nmpa

THOMSON REUTERS
·
Oct 28

Shanghai Junshi Biosciences - Approval Granted for Toripalimab as Monotherapy for Advanced Urothelial Carcinoma

THOMSON REUTERS
·
Oct 28

Junshi Biosciences (01877) Receives Full Approval from NMPA for Toripalimab in Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-Containing Chemotherapy Failure

Stock News
·
Oct 28

Junshi Biosciences Doses First Patient in Phase III Trial of Lymphoma Drug Candidate

MT Newswires Live
·
Oct 26

Junshi Biosciences Initiates Phase III Trial of Bispecific Antibody JS203 in Relapsed/Refractory DLBCL

Bulletin Express
·
Oct 23

Junshi Biosciences Sets 29 October 2026 Board Meeting to Approve Nine-Month 2026 Results

Bulletin Express
·
Oct 15

BNP PARIBAS SA Raises Stake in JUNSHI BIO by 204,800 Shares at HK$17.96 Each

Deep News
·
Oct 05

JUNSHI BIO: BNP PARIBAS SA Acquires Shares, Long Position Rises to 9.05%

HK Disclosure
·
Oct 02

Junshi Bio (01877) Surges Over 4% on Strategic Partnership with Meijie Medical to Explore "Multimodal Drug-Device Combination" in Cancer Treatment

Stock News
·
Sep 30

Junshi Biosciences Swings to Profit on 45% Revenue Surge in 1H 2026, Boosted by Toripalimab Sales and Licensing Income

Bulletin Express
·
Sep 24

Shanghai Junshi Biosciences Grants 715,000 A-Share Options

MT Newswires Live
·
Sep 24

Asian Growth Companies With High Insider Ownership September 2026

Simply Wall St.
·
Sep 22